Encinitas-based Ventyx Biosciences, a clinical-stage biotech company developing oral therapeutics for autoimmune disease, has hired Martin Auster as its chief financial officer.
Prior to joining Ventyx, he served as managing director, biotechnology analyst at Credit Suisse. Prior to Credit Suisse, he was a senior biotechnology analyst at UBS Securities. Prior to that, he served as an executive at Ascendis Pharma and United Therapeutics.
“We are extremely pleased to welcome Marty to the Ventyx team as Chief Financial Officer,” said Raju Mohan, chief executive officer of Ventyx. “Marty is a well-known and highly respected biotechnology leader with a diverse background as a senior research analyst, biotech company executive, and board member. His expertise in corporate strategy and finance, combined with his strong investor relationships, make him an ideal fit for this role as we enter the next phase of growth for Ventyx.”
Ventyx was founded in 2019 by CEO Raju Mohan and Chris Krueger, its chief business officer. Emerging from stealth mode in March, Ventyx Biosciences annouced it raised $114 million in March led by venBio Partners.
It has accumulated assets from two formerly separate companies including Oppilan Pharma, targeting S1P1R and Zomagen Biosciences, targeting the NLRP3 inflammasome. It also has a third asset targeting TYK2.
“The immunology and inflammation space is one of the most rapidly evolving therapeutic categories in biotech today, attracting significant attention from investors, pharmaceutical companies and patient groups. Ventyx’s broad pipeline of therapeutics targeting S1P1R, TYK2, and NLRP3, its accomplished management team, and the support of its high-quality investors make this a compelling opportunity to join the company,” said Auster.
“I look forward to being a part of the Ventyx team and their mission to make a difference in the lives of patients suffering from debilitating autoimmune diseases,” he said.